Research graph
References from Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
10.1182/blood.2020005289 · 2020 · External reference
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
10.3324/haematol.2018.214056 · 2020 · External reference
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial
10.1038/s41375-025-02795-0 · 2026 · External reference
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
10.1182/blood.2019002385 · 2020 · External reference
UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells
10.1182/blood.2019002102 · 2020 · External reference
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in mantle cell lymphoma: results from the EU-MCL network trials
10.1038/s41375-024-02375-8 · 2024 · External reference
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma
10.1038/s41467-025-64666-7 · 2025 · External reference
MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
10.3324/haematol.2019.243071 · 2021 · External reference
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
10.1182/blood-2015-02-628792 · 2015 · External reference
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
10.1172/jci153283 · 2022 · External reference
Secondary genetic events and their relationship to TP53 mutation in mantle cell lymphoma: a sub-study from the FIL_MANTLE-FIRST BIO on behalf of Fondazione Italiana Linfomi (FIL)
10.3390/cancers17244027 · 2025 · External reference
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: a study from the Fondazione Italiana Linfomi (FIL) phase III MCL0208 trial
10.1002/hem3.70285 · 2026 · External reference
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
10.1016/s0140-6736(24)00184-3 · 2024 · External reference
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma
10.1056/nejmoa2201817 · 2022 · External reference
Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma
10.1200/jco-25-00690 · 2025 · External reference
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
10.1016/s2352-3026(25)00252-2 · 2025 · External reference
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
10.1038/s41375-025-02688-2 · 2025 · External reference
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels
10.1182/bloodadvances.2024014136 · 2025 · External reference
CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing
10.1371/journal.pcbi.1004873 · 2016 · External reference
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
10.1038/s41591-019-0380-z · 2019 · External reference
Parent-specific copy number in paired tumor-normal studies using circular binary segmentation
10.1093/bioinformatics/btr329 · 2011 · External reference
A faster circular binary segmentation algorithm for the analysis of array CGH data
10.1093/bioinformatics/btl646 · 2007 · External reference
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma
10.1073/pnas.0710052104 · 2007 · External reference
Maftools: efficient and comprehensive analysis of somatic variants in cancer
10.1101/gr.239244.118 · 2018 · External reference
TP53 gain-of-function and non-gain-of-function mutations are associated with differential prognosis in advanced pancreatic ductal adenocarcinoma
10.1200/po.22.00570 · 2023 · External reference
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma
10.1007/s00277-026-06771-1 · 2026 · External reference
TP53 mutations in mantle cell lymphoma: from backup to game changer
10.3390/jcm14238480 · 2025 · External reference
CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate
10.1084/jem.20211314 · 2022 · External reference
CD36: an emerging therapeutic target for cancer and its molecular mechanisms
10.1007/s00432-022-03957-8 · 2022 · External reference
Deciphering the elevated lipid via CD36 in mantle cell lymphoma with bortezomib resistance using synchrotron-based Fourier transform infrared spectroscopy of single cells
10.3390/cancers11040576 · 2019 · External reference
CD36 drives metastasis and relapse in acute myeloid leukemia
10.1158/0008-5472.can-22-3682 · 2023 · External reference
Role of CD36 in cancer progression, stemness, and targeting
10.3389/fcell.2022.1079076 · 2022 · External reference
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells
10.18632/oncotarget.25066 · 2018 · External reference
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
10.1038/s41375-025-02615-5 · 2025 · External reference
Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma
10.1186/s10020-025-01376-2 · 2025 · External reference
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
10.1038/s41467-018-07729-2 · 2019 · External reference
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
10.1016/s0140-6736(25)01432-1 · 2025 · External reference
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
10.1182/blood.2020008727 · 2021 · External reference
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
10.1182/blood.2024025563 · 2025 · External reference
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
10.1016/s1470-2045(24)00682-x · 2025 · External reference
